作者
Jennifer A. Chan,Susan M. Geyer,Tyler Zemla,Michael V. Knopp,Spencer C. Behr,Sydney Pulsipher,Fang‐Shu Ou,Amylou C. Dueck,Jared D. Acoba,Ardaman Shergill,Edward M. Wolin,Þorvarður R. Hálfdánarson,Bhavana Konda,Nikolaos A. Trikalinos,Bernard Tawfik,Nitya Raj,Shagufta Shaheen,Namrata Vijayvergia,Arvind Dasari,Jonathan Strosberg,Elise C. Kohn,Matthew H. Kulke,Eileen M. O’Reilly,Jeffrey A. Meyerhardt
摘要
Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear.